Until 2015, the epidermal growth factor receptor inhibitor cetuximab, a tumour-specific antibody, represented the only Food and Drug Administration (FDA)-approved targeted therapy for SCCHN. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.